ArticleInternational journal of nanomedicine2026
Levofloxacin-Catalase-PLGA Nanoparticles Potentiate Sonodynamic Therapy to Alleviate BCG-Induced Tuberculous Granulomas via PI3K/Akt/VEGF Pathway Suppression in Rats.
Article in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Hypoxic tuberculous granulomas induce vascular dysfunction and severely impede drug penetration. This study aimed to elucidate the molecular mechanism by which sonodynamic therapy (SDT) induces vascular normalization and synergistic immunomodulatory effects. Methods: Levofloxacin and catalase co-loaded PLGA nanoparticles (LEV@CAT-NPs) were prepared and characterized. Results: LEV@CAT-NPs exhibited excellent stability and oxygen-generating capacity. SDT effectively alleviated intralesional hypoxia and downregulated HIF-1α and VEGF expression, promoting vascular normalization - evidenced by reduced vascular density, increased pericyte coverage, decreased leakage, improved perfusion, and enhanced tight junctions. Mechanistically, SDT inhibited the PI3K/Akt/VEGF pathway, reduced macrophage VEGF secretion, and induced macrophage apoptosis, thereby suppressing abnormal angiogenesis and improving drug penetration. The treatment also activated innate and adaptive immune pathways, promoting CD3⁺ and CD8⁺ T cell infiltration. Conclusion: The SDT-driven mechano-chemical synergistic strategy effectively induces vascular normalization in tuberculous granulomas, improves drug delivery, and offers a promising approach for treating drug-resistant tuberculosis through microenvironment remodeling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.